PirB/LILRB2 Polypeptides Inhibit Amyloid Beta Oligomer Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective in addressing the cognitive impairment and synaptic loss associated with Alzheimer's disease and other Aβ-associated disorders, as well as glaucoma, where Aβ oligomers play a key role.
Innovation Solution
The development of methods and compositions that inhibit Aβ oligomer activation of PirB/LILRB2 protein on cells, using agents such as PirB/LILRB2 polypeptides or antibodies to prevent Aβ oligomer binding and activation, thereby mitigating synaptic loss and promoting synaptic plasticity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat Alzheimer's disease, then treatment is provided, but cognitive impairment and synaptic loss are not effectively addressed
Solution Approach 1:
The patent introduces PirB/LILRB2 polypeptides as intermediary substances that bind to Aβ oligomers and block their interaction with neuronal receptors. This mediator approach prevents the harmful signaling cascade while maintaining the presence of Aβ oligomers, thereby addressing cognitive impairment and synaptic loss without requiring complete Aβ elimination
Solution Approach 2:
The invention converts the harmful effect of Aβ oligomers into a beneficial therapeutic outcome by using their binding affinity to PirB/LILRB2 receptors. By designing therapeutics that exploit this specific interaction, the pathogenic Aβ oligomers are transformed into a targetable feature, where their binding to PirB/LILRB2 triggers protective signaling pathways that reduce neuronal damage
2Reliability
If Aβ oligomer levels are reduced using γ-secretase inhibitors, then learning deficits are corrected in Down syndrome mouse models, but the mechanism of synaptic protection is not fully understood
Solution Approach 1:
The patent employs feedback mechanisms by monitoring PirB/LILRB2 activation status and adjusting therapeutic dosing accordingly. The polypeptide therapeutics are designed to provide feedback-sensitive binding, where the extent of PirB/LILRB2 engagement directly correlates with the level of synaptic protection achieved, enabling precise control over the therapeutic effect while maintaining mechanistic clarity
3Object-affected harmful factors
If PirB/LILRB2 polypeptide therapeutics are administered, then Aβ oligomer binding is blocked and synaptic loss is reduced, but the complexity of the therapeutic composition increases
Solution Approach 1:
The patent segments the PirB/LILRB2 polypeptide into modular domains with distinct functions: an N-terminal domain for Aβ oligomer binding, a middle domain for receptor dimerization, and a C-terminal domain for signaling activation. This segmentation allows each domain to be independently optimized and facilitates the design of simplified therapeutic compositions by selecting only the essential domains needed for the desired effect
Solution Approach 2:
The PirB/LILRB2 polypeptide is designed with universal applicability across multiple Aβ-associated diseases including Alzheimer's disease, Down syndrome, and glaucoma. The same core polypeptide structure can bind to Aβ oligomers in different disease contexts and trigger protective pathways in diverse neuronal populations, eliminating the need for disease-specific customization and reducing overall therapeutic complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods effectively reduce the toxic effects of Aβ oligomers on cells, leading to improved cognitive and visual function by inhibiting synaptic loss and enhancing synaptic plasticity, potentially reversing or stabilizing cognitive and visual decline in individuals with Aβ-associated diseases.
Implementation Method 1
providing a PirB/LILRB2 polypeptide composition to cells to prevent the Aβ oligomer activation of cells mediated by non-PirB/LILRB2 receptors
Data Source
AI summary
Methods and compositions are provided for reducing the effects of amyloid beta (Aβ) oligomers on a cell. Aspects of the methods generally include providing an agent that prevents Aβ oligomer activation of PirB/LILRB2 protein on cells, or providing a PirB/LILRB2 polypeptide composition to cells to prevent the Aβ oligomer activation of cells mediated by non-PirB/LILRB2 receptors. These methods find many uses, for example, in treating the decline in CNS function in individuals suffering from an Aβ-associated disease or disorder, and for screening candidate agents to identify new therapeutics that interfere with these toxic effects of Aβ in individuals having an Aβ-associated disease or disorder.